Sphingolipid-metabolizing enzymes control the dynamic balance of the cellular levels of important bioactive lipids, including the apoptotic compound ceramide and the proliferative compound sphingosine 1-phosphate (S1P). Many growth factors and inflammatory cytokines promote the cleavage of sphingomyelin and ceramide leading to rapid elevation of S1P levels through the action of sphingosine kinases (SK1 and SK2). SK1 and SK2 are overexpressed in a variety of human cancers, making these enzymes potential molecular targets for cancer therapy.
Introduction
Sphingolipids have become a focal point in biological research, with excellent rationale for their manipulation for the treatment of diseases, including cancer (reviewed in (Ogretmen, 2006; Cuvillier, 2007; Huwiler and Zangemeister-Wittke, 2007) ). The parent lipid sphingomyelin is a structural component of cellular membranes, but also serves as the precursor for potent second messengers that have profound cellular effects. Stimulus-induced metabolism of these lipids is critically involved in cancer cell biology and inflammatory diseases, and so this metabolic pathway offers exciting new molecular targets for drug development.
In response to stimuli including growth factors and inflammatory cytokines, sphingomyelin is enzymatically hydrolyzed to ceramide, which can be further hydrolyzed by the action of ceramidase to produce sphingosine. Ceramide and sphingosine induce apoptosis in cancer cells by mechanisms that remain to be elucidated.
Sphingosine is rapidly phosphorylated by sphingosine kinase (SK) to produce sphingosine 1-phosphate (S1P), which is mitogenic and anti-apoptotic. Through these conversions, a critical balance, i.e. a ceramide / S1P rheostat, has been hypothesized to determine the fate of the cell (Cuvillier et al., 1996) . In this model, the balance between the cellular concentrations of ceramide and S1P determines whether a cell proliferates or undergoes apoptosis. Upon exposure to mitogens or activation of intracellular oncoproteins, the cells experience an increase in the intracellular levels of S1P and depletion of ceramide levels, and this situation promotes cell survival and proliferation. In 5 specific inhibitors of SK as they have been shown to affect protein kinase C (Igarashi et al., 1989 ), 3-phosphoinositide-dependent kinase (King et al., 2000) , and casein kinase II (McDonald et al., 1991) . Additionally, the compound phenoxodiol has been described as an SK inhibitor (Gamble et al., 2006) ; however, this isoflavone also inhibits several other enzymes. A few natural product inhibitors of SK have been isolated (Kono et al., 2001 ), but their selectivities remain unknown and their amenability to large-scale production is doubtful.
Clearly, inhibitors of SK that can be easily synthesized would be highly desirable for evaluating this enzyme as a therapeutic target. To address this problem, we previously identified and characterized structurally novel inhibitors of SK French et al., 2006) . These compounds, called SKI-I, -II and -V, inhibited S1P formation in intact cells, induced apoptosis, and demonstrated antitumor activity upon intraperitoneal administration , reinforcing the approach of targeting SK in cancer. We report here the pharmacologic characterization of a new orally-available SK inhibitor with in vivo activity.
Importantly, this compound is selective for SK2, thereby providing the first pharmacologic probe to evaluate the biological roles of this SK isozyme.
This article has not been copyedited and formatted. The final version may differ from this version. Fibronectin and cell culture inserts were purchased from BD Biosciences (San Jose, CA).
Recombinant human SK1 and SK2 were purchased from BPS Biosciences (San Diego, CA).
C 17 -sphingosine and C 17 -S1P were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL).
All cell lines were obtained from the American Type Culture Collection and grown in either DMEM or RPMI 1640 medium containing 10% fetal bovine serum and 50 µg/ml gentamycin sulfate. ABC294640, 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (Figure 1 ), was synthesized as described previously (Maines et al., 2008) . The hydrochloride salt, ABC294640 • HCl, was prepared by dissolving 9.6 g of ABC294640 in 50 mL of CH 2 Cl 2 , and slowly adding an equimolar amount of 1M HCl in ether. After filtration and washing, 9.6 g (93%) of ABC294640 • HCl was recovered as fine crystals with a melting point of 204 -206 ºC.
Sphingosine kinase assays. The IC 50 s for ABC294640 and DMS were determined by a newly-developed HPLC-based SK activity assay. Briefly, the test compounds were incubated with recombinant SK1 or SK2 and omega(7-nitro-2-1,3-benzoxadiazol-4-yl)(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol (NBD-Sph) in the isozyme-selective assay buffers detailed below with 1 mg/ml fatty acid-free BSA, 100 µM ATP and 400 µM MgCl 2 . The product, i.e. NBD-S1P, was separated from NBD-Sph by HPLC as follows: Waters 2795 HPLC system with a Waters 2495 fluorescence detector, C8 Chromolith RP-8e column (100 × 4.6 mm, Merck KGaA, Germany), 1 ml/min mobile phase (acetonitrile : 20 mM (pH2.5) sodium phosphate buffer at 45 : 55). Fluorescence was monitored with excitation at 465 nm and emission at 531 nm. The ratio of NBD-S1P / (NBD-Sph + NBD-S1P) was used as a measure of SK activity. SK-isozyme selective assay buffers each contained 20 mM Tris pH7.4, 5 mM EDTA, 5 mM EGTA, 3 mM This article has not been copyedited and formatted. The final version may differ from this version. 7 beta-mercaptoethanol, 5% glycerol, 1X protease inhibitors (Sigma, USA) and 1X phosphatase inhibitors (Roche, USA). For the SK1 assay buffer, 0.25% (final) Triton X-100 was added; and for the SK2 buffer, 1M (final) KCl was added. Assays were run for 2 hr at room temperature, and then a 1.5 volume of methanol was added to terminate the kinase reaction. After 10 min, the samples were centrifuged at 20,000 x g to pellet the precipitated protein, and the supernatants were analyzed by HPLC. In experiments to determine the K i for inhibition of SK2 by ABC294640, the ADP Quest assay system (DiscoveRx Corporation, Fremont CA) was used to measure kinase activity in the presence of varying concentrations of sphingosine and ABC294640.
To determine the effects of ABC294640 on cellular SK activity, near-confluent MDA-MB-231 cells were serum-starved overnight, and then treated with varying concentrations of ABC294640. The cells were then incubated with [ 3 H]sphingosine at a final concentration of 1 μ M as previously described the cellular sphingolipids were based on the calibration curves generated by spiking an artificial matrix with known amounts of target standards and an equal amount of the internal standard.
The target analyte to internal standard peak area ratios from the samples were similarly normalized to their respective internal standards and compared to the calibration curves by linear regression. Final results were expressed as the level of the particular sphingolipid Chemotaxis and cytoskeletal assays. Chemotaxis assays were performed as follows:
Transwell inserts (8 µm pore size) were pre-coated with fibronectin (5 µg/ml) for 1 h at room temperature. A-498 cells were trypsinized and resuspended in serum-free media at a concentration of 10 5 cells/ml. A total volume of 500 µl of this cell suspension was added to the top of the insert and medium containing 10 % fetal bovine serum was placed at the bottom to act as a chemoattractant. Equal concentrations of ABC294640 were added to the top and the bottom of the chamber. After 4 h at 37 o C, cells that migrated through the membrane were fixed in 4 % formaldehyde and stained with crystal violet. The G (globular) to F (fibrous) actin ratio was quantified to assess the status of microfilaments. Briefly, cells were exposed to the drug for various times and actin was extracted by washing the cells with 1% Triton X-100 solution in PBS. The two forms of actin were separated by centrifugation at 14,000 x g. The supernatant (containing G actin) was mixed 1:1 with Laemmli buffer and the pellet (containing F actin) was dissolved in Laemmli buffer.
Samples were subjected to SDS-PAGE and the actin content of each fraction was quantified by immunoblotting with anti-actin antibody and analyses using the ImageJ (NIH) program. 10 381 and 426, respectively). Peak areas were integrated using Xcalibur software, and ABC294640 concentrations determined from a standard curve, which was linear in range of all plasma levels observed in these studies.
Oral bioavailability and pharmacokinetic studies. Formulations of ABC294640 • HCl were administered orally or intravenously to fasted female Swiss-Webster mice at a dose of 100 mg/kg in 0.1 mL of the indicated solvents. Blood samples were removed at 1 and 7 hr after dosing, and the plasma concentration of ABC294640 was determined by reverse-phase LC/MS running in SIM mode as described above. For pharmacokinetic studies, female Swiss-Webster mice (6-8 weeks old) were fasted overnight and administered a bolus dose of 0.1 mL of ABC294640 • HCl either orally or intravenously. After dosing, mice were anesthetized with halothane and blood was removed via intracardiac puncture at the indicated times. Plasma samples were processed and ABC294640 levels were determined as described above.
Noncompartmental pharmacokinetic analyses were performed using WINNONLIN (Pharsight).
Toxicology studies. Acute (7-day) and chronic (28-day) toxicology studies were conducted with ABC294640 • HCl. In the first study (which was conducted by Eurofins | Product Safety Laboratories, Dayton, NJ), Sprague-Dawley male rats (7-8 weeks old) were orally dosed with 0, 100 or 250 mg of ABC294640 • HCl /kg in 0.375% Polysorbate-80 in PBS daily for 7 days. The animals were observed daily for viability, signs of gross toxicity, and behavioral changes, and a battery of detailed observations were performed on study Days 1 and 7. Blood was sampled from all animals on Day 8 of the study for hematology, clinical biochemistry and serology assessments, and the animals were sacrificed. Gross necropsies were performed on all study rats, and selected organs and tissues were evaluated in the control and high-dose level groups.
In the second study, C57BL/6 mice were orally dosed with 0, 100 or 250 mg of ABC294640 • This article has not been copyedited and formatted. The final version may differ from this version. 12 tumor slices were homogenized in ice-cold PBS to a final concentration of 10 mg/mL. A 0.5 mL aliquot of the homogenate was combined with 0.5 mL of methanol, 0.25 mL of chloroform, and 375 pmol each of internal standards C 17 -sphingosine and C 17 -S1P. Blank samples spiked with known amounts of sphingosine, S1P and the internal standards were processed in parallel to provide a standard curve for quantification. After sonication, samples were incubated overnight at 48 ºC, followed by addition of 75 μ L of 1N potassium hydroxide in methanol. The samples were then sonicated and incubated at 37 ºC for 2 hr. A portion (0.4 mL) of each sample was then transferred to a new tube, dried, reconstituted in 0.25 mL of Phase A, filtered and transferred to a vial. HPLC was performed as described above. Elution was performed at 0.45 mL/min with 65% Phase B for 2 min followed by a linear gradient to 100% Phase B over 5 min.
Ions for C 17 -sphingosine, sphingosine, C 17 -S1P and S1P were monitored at m/z 286 (parent ion) 268 (daughter ion), 300 282, 366 250 and 380 264, respectively. Similarly, extracts of tumors from ABC294640-treated mice were prepared and levels of ABC294640 were quantified by LC/MS as described above.
This article has not been copyedited and formatted. The final version may differ from this version. congeners were synthesized and tested for their ability inhibit a recombinant fusion protein of GST and human SK1 . The structure-activity properties of this series will be reported elsewhere. Although ABC294640 is not the most potent SK inhibitor in this series, its biologic and pharmacologic properties were characterized because of its excellent solubility and oral absorption (described below), and in vivo activity in models of diabetic retinopathy (Maines et al., 2006) and ulcerative colitis (Maines et al., 2008) .
In evaluating the potencies of these compounds, we developed an HPLC-based assay for SK activity that avoids the use of radiolabeled substrate as we have previously described . Activities were normalized to vehicle-treated (DMSO) control reactions. As indicated in Table 1, none of the other 20 diverse kinases tested were significantly inhibited by the compound.
These data suggest that the biological effects of this compound are not mediated by off-target inhibition of protein kinases, consistent with its targeting of the sphingosine binding site of SK2.
This article has not been copyedited and formatted. The final version may differ from this version. Figure 3 , the predominant molecular species of ceramide in untreated cells included C 16 -ceramide, C 22 -ceramide, C 24 -ceramide and C 24:1 -ceramide. Each of these molecular species of ceramide was elevated after 12 and 24 hr of ABC294640-treatment, but these changes were largely normalized by 48 hr of treatment. Interestingly, the cellular levels of dihydro-C16-ceramide were dramatically and persistently elevated by treatment with ABC294640, as were levels of dihydro-sphingosine. Importantly, cellular S1P levels were decreased at all times of ABC294640-treatment, particularly in cells treated for 48 hr.
Therefore, ABC294640 markedly alters the ratio of ceramide : S1P consistent with inhibition of SK activity.
Inhibition of tumor cell proliferation and migration by ABC294640. The effects of ABC294640 on the proliferation of human tumor cell lines representing major tumor types were determined using the sulforhodamine B assay for quantifying cell number. As indicated in Table   2 Binding of S1P to G protein-coupled S1P receptors induces a plethora of biological effects, including rapid reorganization of the actin cytoskeleton and stimulated migration of the cells (Hait et al., 2006) . Therefore, we hypothesized that inhibition of SK activity by ABC294640
will affect microfilament structure and the ability of cells to migrate. A-498 cells are highly metastatic and mobile, which allowed us to perform migration assays using Boyden chambers for a short time (4 hr). As shown in Figure 4A , even short exposure to ABC294640 affected the ability of A-498 cells to migrate through a filter. This was confirmed using the "scratch assay", which measures haptokinetic (random) cell movement (data not shown). Since cell migration is dependent on the microfilament cytoskeleton, A-498 cells were treated with ABC294640 and actin fibers were stained with FITC-phalloidin and observed by confocal microscopy.
Representative images from those experiments are presented in Figure 4C , in which actin fibers are stained green, and nuclei are stained blue with DAPI. Cytochalasin D was used as a positive control for microfilament depolymerization. At the 24 h time point and concentrations of 50 µM or higher, the most noticeable phenotypes were a decrease in the number of stress fibers in the cells and a decrease in the number of lamellipodia protruding from the cell surface.
Reorganization of actin structure was confirmed by separating and measuring the globular (G) and fibrous (F) actin levels. As shown on Figure 4B , the increase in G/F actin ratio is consistent with the changes in actin structure observed by confocal microscopy. (PG), 100% polyethylene glycol 400 (PEG400), 50% PEG400 or 0.375% Polysorbate-80 did not precipitate (measured as turbidity at 590 nm), and so were administered to fasted female SwissWebster mice at a dose of 100 mg/kg. Blood samples were removed at 1 and 7 hr, and plasma levels of ABC294640 were determined using an internal standard and reverse-phase HPLC coupled to an ion-trap quadrupole mass spectrometer running in positive SIM detection mode.
As shown in Table 3 , substantial amounts of ABC294640 were detected in the blood 1 hr after oral dosing, with the highest levels attained in the samples formulated in 90% PG. It should be noted that these ABC294640 concentrations are sufficient to inhibit SK activity and proliferation of tumor cells. By 7 hr, the plasma concentrations decreased by approximately 50% in most cases. Effective absorption was observed in the sample formulated in 0.375% Polysorbate-80, and this solvent for ABC294640 • HCl was used in further pharmacokinetic and efficacy analyses because of its low toxicity.
To further understand the absorption properties of ABC294640 • HCl, the relationship between plasma concentration and dose was examined. Mice were orally dosed with 10, 35 or 100 mg/kg of ABC294640, and the plasma levels were determined at 30 min. As shown in Figure 5 , the plasma ABC294640 values demonstrated a good linear response with doses up to at least 100 mg/kg.
Pharmacokinetics of ABC294640.
Detailed pharmacokinetic studies were performed on ABC294640 • HCl in 0.375% Polysorbate-80. Female Swiss-Webster mice were dosed with 50 mg/kg ABC294640 either intravenously or orally. Groups of mice (3 per group) were anesthetized and blood removed via cardiac puncture at time points ranging from 1 min to 7 hr.
Plasma concentrations of ABC294640 were determined by LC/MS and pharmacokinetic parameters were calculated using the WINNONLIN software package (Table 4) . Intravenous toxic effects were observed after administration of doses up to 1000 mg/kg. Therefore, the compound was considered to be suitable for more detailed in vivo studies.
Non-GLP acute toxicology studies were contracted to Eurofins
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Laboratories, in which ABC294640 • HCl was given orally in 0.375% Polysorbate-80 to rats at doses of 0, 100 or 250 mg/kg daily for 7 days. There were no clinical observations or gross findings that were considered to be the result of ABC294640 • HCl administration or otherwise.
There were no significant changes in total body weight of the treated animals, although there was a slight decrease in body weight gain, consistent with a small decrease in food consumption, in the high-dose rats. Hematology studies (Table 5) Similarly, there were no treatment-related microscopic changes in any organ examined in the high-dose group, except for a slight decrease in the background level of extrameduallary hematopoiesis in the spleen which may underlie the small decreases in the hematocrit.
To further characterize the hematologic changes observed in the acute study, mice were treated with 0, 100 or 250 mg ABC294640 • HCl / kg daily for 28 days. As indicated in Figure   6A , mice treated with 250 mg/kg experienced a 20% decrease in red blood cell count and hematocrit, and a modest increase in the number of circulating neutrophils on Day 7, essentially identical to the previous study with rats. However, after 28 days of treatment ( Figure 6B ), these parameters were restored to normal levels, indicating that the animals had fully recovered from any transient impairment of hematopoiesis. Additionally, there were no changes in the brain or spleen weights of treated mice, whereas a slight decrease (12%) in liver weight was observed in mice treated with 250 mg/kg.
Antitumor activity of ABC294640. The antitumor activity of ABC294640 • HCl was tested in a syngeneic tumor model that uses the mouse JC mammary adenocarcimona cell line growing subcutaneously in immunocompetent Balb/c mice . Because of the excellent oral absorption described above, we determined the ability of orally-delivered ABC294640 • HCl to reduce tumor growth in vivo. The SK inhibitor was administered to fasted mice on odd days at doses ranging from 3.5 to 100 mg/kg. Body weights and tumor volumes were monitored daily. As demonstrated in Figure To determine a mechanistic pharmacodynamic endpoint for ABC294640 • HCl, we quantified sphingolipid metabolites in the tumors by LC-MS/MS. Samples of frozen tumors removed at the end of the study in Figure 7 were homogenized in cold PBS, spiked with internal standards and processed by liquid-liquid extraction. Ratios of sphingosine and S1P to internal standards were determined and compared with vehicle-treated tumor samples. As shown in Figure 8C , treatment of the mice with ABC294640 • HCl at the 100 mg/kg had no effect on 
Discussion
Accumulating evidence demonstrates that S1P is a critical second messenger that exerts proliferative, antiapoptotic and inflammatory actions. An oncogenic role of SK has been directly demonstrated since transfection into NIH/3T3 fibroblasts was sufficient to promote foci formation and cell growth in soft-agar, and to allow these cells to form tumors in NOD/SCID mice (Xia et al., 2000) . Additionally, inhibition of SK by transfection with a dominant-negative SK mutant or by treatment of cells with the nonspecific SK inhibitor DMS blocked transformation mediated by oncogenic H-Ras. As abnormal activation of Ras frequently occurs in cancer, these findings suggest a significant role of SK in this disease. SK has also been linked to estrogen signaling (Sukocheva et al., 2003) , and estrogen-dependent tumorigenesis in MCF-7 cells (Nava et al., 2002) . Other pathways or targets to which SK activity has been linked in cancer include VEGF signaling via the Ras and MAP kinase pathway (Shu et al., 2002) , protein kinase C (Nakade et al., 2003) , TNFα (Vann et al., 2002) and caspase activation (Edsall et al., 2001 ). Angiogenic factors and processes, such as cell motility, mitogenesis in smooth muscle cells, endothelial cell differentiation and growth factor signaling are also affected by SK and S1P (Lee et al., 1999) . While the elucidation of downstream targets of S1P remains an interesting problem in cell biology, sufficient validation of these pathways has been established to justify their evaluation as targets for new types of anticancer drugs. As S1P appears to be the most direct mitogenic messenger, inhibition of its production should have useful antiproliferative effects on tumor cells.
Two isozymes of SK (termed SK1 and SK2) exist (Kohama et al., 1998) , with SK2 being cloned in 2000 (Liu et al., 2000) . However, the roles of these SK isozymes remain to be defined SK2, in MCF-7 cells (Doll et al., 2005) ; however, it has also been reported that EGF activates SK2 in MDA-MB-453 cells . Overexpression of SK1 has been shown to be oncogenic in a variety of cells (Xia et al., 2000; French et al., 2003; Le Scolan et al., 2005) ; whereas overexpression of SK2 is reported to inhibit cell growth and to induce apoptosis . However, these effects of SK2 are only partially dependent on its catalytic activity, suggesting that the antiproliferative effects may be mediated by its BH3
domain . Consistent with this, are the observations that physiological levels of SK2 do not inhibit DNA synthesis (Okada et al., 2005) . SK1-deleted transgenic mice have normal phenotypes, and serum concentrations of S1P are reduced by 50%. However, levels of S1P within a variety of tissues are not different from those of control mice, indicating functional replacement of SK1 by SK2 in normal tissues (Allende et al., 2004) . Similarly, genetic ablation of SK2 results in mice with normal fertility and life-span, and 25% reduced serum S1P levels (Kharel et al., 2005) . Our data , and that of others (Johnson et al., 2005; Van Brocklyn et al., 2005; Kawamori et al., 2006) , demonstrate that SK1 is marked overexpressed in a variety of human cancers, while SK2 is typically not (Van Brocklyn et al., 2005) , although several types of cancer do have elevated levels of SK2 message (unpublished observations). Therefore, it was unclear if selective targeting of SK1 or SK2 by SK inhibitors will be sufficient to inhibit tumor growth and induce apoptosis, or whether simultaneous inhibition of SK1 and SK2 will be necessary to prevent the functional redundancy of these isozymes.
Based upon this growing body of knowledge implicating SKs in the abnormal growth of cancer cells, we sought to identify novel inhibitors of SK1 and/or SK2 that may serve as effective cancer therapeutics. Screening a chemically diverse small molecule library using a recombinant human SK1-fusion protein resulted in the identification of multiple chemotypes . Follow up hit-to-lead efforts resulted in the discovery of ABC294640, an aryladamantane compound with SK inhibitory activity . The potency of ABC294640 is similar to other SK inhibitors described in the literature (Kono et al., 2001 );
This article has not been copyedited and formatted. The final version may differ from this version. Figure 2B ). Since the levels of sphingosine in a cell are very low, e.g. in comparison with ceramide levels (Figure 3) , inhibition of SK2 by ABC294640 is likely to be very efficient. The selective targeting of SK2 was unexpected; however, our studies using siRNAs directed at either SK1 or SK2 demonstrate that ablation of SK2 from tumor cells has greater antiproliferative and anti-migratory affects than does depletion of SK1 2 . Since many kinase
inhibitors lack specificity, we tested the ability of ABC294640 to inhibit several other kinases.
These assays indicated that ABC294640 is highly specific for SK versus protein kinases, making it a viable candidate chemotherapeutic agent.
Our studies on the chemicophysical properties of ABC294640 further support its development. For example, the presence of the pyridine moiety permits protonation of the nitrogen atom, and the formation of a hydrochloride salt. This greatly improves the solubility, such that ABC294640 • HCl was quite soluble in almost all tested carriers. These broad solubility properties enabled testing multiple formulations to evaluate their respective in vivo absorption properties. While all formulations showed encouraging results, we chose 0.375% Polysorbate-80 due to its ease of formation and lower viscosity, which facilitates oral dosing.
Additionally, long term stability studies revealed that ABC294640 • HCl was highly stable in 0.375% Polysorbate-80 versus the other formulations (data not shown).
Identification of an optimal oral formulation permitted acute and chronic toxicology studies, where we observed excellent toxicity profiles for ABC294640 • HCl. A dose of 100 mg/kg, which was determined to be at least 10-fold below than the lowest observed adverse effect level, resulted in ABC294640 plasma levels that exceeded the IC 50 towards human SK2
and are sufficient for suppression of tumor cell proliferation and migration. Biodistribution inhibitors . Furthermore, tumor growth inhibition correlated with progressive tumor cell apoptosis and decreases in S1P levels in the tumors when compared to vehicletreated mice. This is the first pharmacodynamic evidence of S1P modulation linked to antitumor activity. We believe that this finding, in conjunction with low toxicity of ABC294640 • HCl, provides validation of SK2 as a chemotherapeutic target.
Current studies are underway to determine the mechanism of antitumor activity, since SK activity has been linked to survival, inflammatory and angiogenic pathways. Ideally, SK2
inhibition could lead to modulation of all of these pathways, resulting in tumor inhibition through multiple mechanisms. We also determined that sphingosine levels remained unchanged despite decreases in S1P. This likely relates to an increase in synthesis of ceramide from sphingosine, resulting in a constant sphingosine level. This would be beneficial in a tumor environment, as increases in ceramide levels cause apoptosis in cancer cells (Kolesnick and Fuks, 2003) , and this does occur in the ABC294640-treated tumor cells. Interestingly, we found that SK2 inhibition affects actin structure at time points and concentrations that are non-toxic, suggesting that the compound may also have anti-metastatic activity in vivo.
In conclusion, ABC294640 • HCl is a first-in-class inhibitor of SK with good pharmacologic properties, low toxicity and anticancer activity. These data support our previous demonstrations that ABC294640 • HCl has therapeutic activity in inhibiting diabetes-induced retinal vascular leakage in rats (Maines et al., 2006) and dextran sulfate sodium-induced ulcerative colitis in mice (Maines et al., 2008 Other labels refer to dihydro-C16-ceramide (DHC16-Cer), dihydrosphingosine (DHSph), dihydrosphingosine 1-phosphate (DhSph-1P), sphingosine (Sph) and S1P.
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